BRANDICOURT OLIVIER 4

What Happened

• Olivier Brandicourt, a director at Alnylam Pharmaceuticals (ALNY), was granted two awards on May 20, 2026: 671 shares represented by restricted stock units (RSUs) and a 1,441-share derivative award. Both awards show an acquisition price of $0.00 (i.e., they were granted, not purchased), with total reported cash value $0.
• These are compensatory awards (not open-market purchases or sales) — typically routine director compensation rather than an immediate market bet.

Key Details

• Transaction date: May 20, 2026; Form filed May 22, 2026 (appears timely).
• Awards: 671 RSUs (footnote F1) and 1,441-share derivative award (footnote F2). Price per share reported $0.00.
• Vesting/conditions: F1 — RSUs represent a contingent right to one share each; vest in full on the earlier of the first anniversary of the grant or earlier retirement/resignation if that occurs no more than 90 days before the first anniversary. F2 — the derivative (stock option-style) award will vest in full on the same schedule/conditions described above.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Transaction type codes: A = Award/Grant. Not a sale or open-market purchase.

Context

• Awards and RSUs are common components of director compensation and do not represent an immediate cash outlay or sale of shares; they indicate future potential ownership contingent on vesting.
• Because these were grants at $0, there was no immediate realized value — any value accrues only if/when the awards vest and are converted into shares.